SAN DIEGO, Nov. 9 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2007 financial results after the close of market on Wednesday, November 14, 2007.
Cadence management will host a conference call and live webcast to discuss the financial results and provide a corporate overview on Thursday, November 15, 2007 at 8:30 am Eastern Time (5:30 am Pacific Time). Interested investors may participate in the conference call by dialing 800-289-0461 (domestic) or 913-312-6680 (international). To access the webcast, please log on to the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
principally for use in the hospital setting. The company currently has two
Phase III product candidates in development, including intravenous
acetaminophen (IV acetaminophen) for the treatment of acute pain and fever,
and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the
prevention of catheter-related infections. For more information about
Cadence's pipeline, visit http://w
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved